Literature DB >> 17072491

Antiflammin-2 activates the human formyl-peptide receptor like 1.

Ahmad M Kamal1, Richard P G Hayhoe, Anbalakan Paramasivam, Dianne Cooper, Roderick J Flower, Egle Solito, Mauro Perretti.   

Abstract

The anti-inflammatory actions of the nonapeptide antiflammin-2, identified by homology with uteroglobin and annexin-A1 sequences, have been described in some detail, yet its mechanisms of action remain elusive. Since recent data indicate an involvement of the formyl peptide receptor (FPR)-like 1 (or FPRL-1) in the effects of annexin-A1, we have tested here the effect of antiflammin-2 with respect to this receptor family. Using HEK-293 cells expressing either human FPR and FPRL-1, and an annexin-A1 peptide as tracer ([125I-Tyr]-Ac2-26), we found that antiflammin-2 competed for binding only at FPRL-1, and not FPR, with an approximate EC50 of 1 mM. In line with data produced for the full-length protein, genuine receptor activation by antiflammin-2 was confirmed by rapid phosphorylation of extracellular-regulated kinase 1 and 2. Finally, study of the neutrophil interaction with activated endothelium under flow demonstrated an inhibitory effect of antiflammin-2, thus providing functional support to a role for the antiflammin-2/FPRL-1 anti-inflammatory axis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072491      PMCID: PMC1868079          DOI: 10.1100/tsw.2006.247

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  39 in total

1.  The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells.

Authors:  C Zouki; S Ouellet; J G Filep
Journal:  FASEB J       Date:  2000-03       Impact factor: 5.191

2.  A calcium-driven conformational switch of the N-terminal and core domains of annexin A1.

Authors:  Anja Rosengarth; Hartmut Luecke
Journal:  J Mol Biol       Date:  2003-03-07       Impact factor: 5.469

Review 3.  Formyl-peptide receptors revisited.

Authors:  Yingying Le; Philip M Murphy; Ji Ming Wang
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

4.  Folding energetics of ligand binding proteins II. Cooperative binding of Ca2+ to annexin I.

Authors:  A Rosengarth; J Rösgen; H J Hinz; V Gerke
Journal:  J Mol Biol       Date:  2001-03-02       Impact factor: 5.469

5.  The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.

Authors:  C Dahlgren; T Christophe; F Boulay; P N Madianos; M J Rabiet; A Karlsson
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

Review 6.  Analysis of the protection afforded by annexin 1 in ischaemia-reperfusion injury: focus on neutrophil recruitment.

Authors:  M La; A Tailor; M D'Amico; R J Flower; M Perretti
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

7.  Antiflammin-2 prevents HL-60 adhesion to endothelial cells and prostanoid production induced by lipopolysaccharides.

Authors:  J J Moreno
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

8.  The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.

Authors:  R He; L Tan; D D Browning; J M Wang; R D Ye
Journal:  J Immunol       Date:  2000-10-15       Impact factor: 5.422

9.  The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.

Authors:  T Christophe; A Karlsson; C Dugave; M J Rabiet; F Boulay; C Dahlgren
Journal:  J Biol Chem       Date:  2001-04-02       Impact factor: 5.157

10.  Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.

Authors:  Mauro Perretti; Nan Chiang; Mylinh La; Iolanda M Fierro; Stefano Marullo; Stephen J Getting; Egle Solito; Charles N Serhan
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  9 in total

1.  Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.

Authors:  Vincenzo Brancaleone; Jesmond Dalli; Stefania Bena; Roderick J Flower; Giuseppe Cirino; Mauro Perretti
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

2.  Inhibition of formyl peptide receptor 1 activity suppresses tumorigenicity in vivo and attenuates the invasion and migration of lung adenocarcinoma cells under hypoxic conditions in vitro.

Authors:  Bo Huang; Hongrong Guo; Jie Ding; Jun Li; Hongjuan Wang; Jianqun Xu; Quan Zheng; Lijun Zhou; Qin Dai
Journal:  Ann Transl Med       Date:  2020-09

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

Review 4.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

5.  Uteroglobin, a possible ligand of the lipoxin receptor inhibits serum amyloid A-driven inflammation.

Authors:  Giovanni Antico; Monica Aloman; Katja Lakota; Lucio Miele; Stefano Fiore; Snezna Sodin-Semrl
Journal:  Mediators Inflamm       Date:  2014-03-23       Impact factor: 4.711

6.  Divergent Annexin A1 expression in periphery and gut is associated with systemic immune activation and impaired gut immune response during SIV infection.

Authors:  Angela A S Sena; Tiffany Glavan; Guochun Jiang; Sumathi Sankaran-Walters; Irina Grishina; Satya Dandekar; Luiz R Goulart
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 7.  Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury.

Authors:  Junaid Ansari; Gaganpreet Kaur; Felicity N E Gavins
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

Review 8.  Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury?

Authors:  Felicity N E Gavins
Journal:  Trends Pharmacol Sci       Date:  2010-05-17       Impact factor: 14.819

Review 9.  Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance.

Authors:  Michelle Amantéa Sugimoto; Juliana Priscila Vago; Mauro Martins Teixeira; Lirlândia Pires Sousa
Journal:  J Immunol Res       Date:  2016-01-13       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.